ArticleThe American journal of pathology1997
Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization.
Article in The American journal of pathology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 96 citations in OpenAlex.
- Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics.British journal of cancer · 1999Trial
- Expression of Her2-Neu in Primary Gastric and Gastroesophageal Adenocarcinoma: An Experience from a Tertiary Center in South India.South Asian journal of cancer · 2025Article
- Article
- Prognostic significance of Human epidermal growth factor receptor-2 expression in patients with resectable gastric adenocarcinoma.World journal of surgical oncology · 2019Article
- HER2, NF-Disease markers · 2019Article
- Human epidermal growth factor receptor 2 (HER-2) status evaluation in advanced gastric cancer using immunohistochemistry versus silver in situ hybridization.Bosnian journal of basic medical sciences · 2017Article
- Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Samples of Gastric and Gastro-Esophageal Junction Cancer.Journal of gastric cancer · 2017Article
- The prognostic value of HER-2/neu overexpression in colorectal cancer: evidence from 16 studies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.World journal of gastroenterology · 2014Review
- Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2014Article
- HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridization.American journal of clinical pathology · 2012Article
- HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature.Journal of Cancer · 2012Article
- Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model.Cell stress & chaperones · 2011Article
- HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).Histopathology · 2011Article
- Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.Cell stress & chaperones · 2011Article
- Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model.Cell stress & chaperones · 2010Article
- TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.Histopathology · 2010Article
- HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study.Journal of cellular and molecular medicine · 2009Article
- HER-2/neu overexpression is an independent prognostic factor in colorectal cancer.International journal of colorectal disease · 2007Article
- Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.Cancer immunology, immunotherapy : CII · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amplification of the c-erbB-2 gene was examined in 120 gastric adenocarcinomas by dual-color fluorescence in situ hybridization (FISH) using probes for centromere 17 and the 17q11.2-12. The results were compared with Southern blot analysis and immunohistochemistry of c-erbB-2 overexpression. FISH was successful in 105 tumors, and the amplification was found in 19 tumors. FISH on 17 tumors revealed high-level amplification; in 15, the predominant cancer populations had amplified c-erbB-2 gene with the signals forming one or two clusters, indicating that the amplified gene was present in homogeneously staining regions. In two tumors, most cancer cells had multiple scattered c-erbB-2 signals, indicating that the amplicon was within double-minute chromosomes. The other two tumors had a few additional copies of the c-erbB-2 gene. Seventeen tumors had increased numbers of the gene probably due to polysomy 17, and sixty-nine tumors had no aberrations of chromosome 17. Immunohistochemically, distinct membrane staining was found only in the 17 tumors with the high-level amplification. It is concluded that, in gastric adenocarcinomas, high-level amplification produces the c-erbB-2 gene principally in homogeneously staining region form and occasionally in double-minute form and is thought to control the over-expression of the protein in the cytoplasmic membrane.
Indexed as
Identifiers
9284825PMC1857861W1602850447What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.